Clinical trial registry record

Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Terminated.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated June 5, 2017.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT01220297
Last registry update
June 5, 2017
Status
Terminated
Phase
Phase 2
Sponsor
Stanford University
Enrollment
3
Countries
United States
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
NON RANDOMIZED · PARALLEL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
3
Population
ALL · 2 Years to 60 Years
Duration
2006-08-01 to 2011-08-01
Intervention
Sirolimus; Mycophenolate mofetil (MMF); Carmustine; Etoposide; Cyclophosphamide (Cyclo, CY); FTBI
Comparator
Not reported
Outcomes measured
Acute Graft-vs-Host Disease (GvHD) (Grade 2 to 4) — 100 days post-transplant; Acute GvHD (Grade 3 to 4) — 100 days post-transplant; Disease-free Survival (DFS) — 2 years; Overall Survival — 2 years; Veno-occlusive Disease (VoD) — 100 days post-transplant
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Rapamycin · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

rapamycin
Read the original source →Export JSON